In the tightly regulated landscape of pharmaceutical and biopharmaceutical manufacturing, maintaining contamination-free environments is not merely best practice, it is a regulatory necessity. A planned, controlled and documented cleaning and disinfection regime plays a pivotal role in ensuring that cleanroom environments remain compliant, and safe for production. Disinfectant efficacy validation is a key factor in ensuring that any disinfectants that are selected and used can provide the level of control required to manage maintain acceptable bioburden levels.
Traditionally, companies have relied on in-house or sponsored third-party laboratory testing to validate the effectiveness of disinfectants against the specific material surfaces in each facility. However, with the emergence of scientifically robust supplier data platforms, the industry has travelled some way in considering and accepting a combined approach of using both internally generated validation data and disinfectant manufacturer/supplier data to improve efficiency, cost and resources required for disinfectant validation.
This article explores the rationale behind this shift, the regulatory alignment supporting it, the operational benefits it offers, and the challenges it presents. It also outlines a governance framework to ensure that supplier-generated data can be used, whilst still maintaining scientific integrity and regulatory compliance.
The Traditional Approach: Valuable but Redundant
Historically, disinfectant efficacy validation has involved rigorous testing of a panel of microorganisms representing a variety of differing organism types including gram negative and gram positive bacteria, fungi and bacterial spores. End users will commonly utilize compendial organisms such as those listed in USP<1072> and may include those anticipated to be found in the cleanroom environment. When identified through an environmental monitoring program, specific facility isolates are also added to the validations scope. Disinfectant efficacy testing against the selected microorganisms is then performed on surface materials representative of those present in the cleanroom, under simulated laboratory conditions.
While this method ensures that the disinfectants are effective against the specific biocide/surface/organism combination within a specified contact time against specific surfaces, this testing can be time-consuming, resource-intensive, and often duplicative, particularly if a reputable supplier has already commissioned comprehensive studies using standardized methodologies.
Moreover, internal laboratory testing by the end user may not always match the methodological rigor or reproducibility of supplier-generated data. End users and suppliers often outsource disinfectant efficacy testing to third-party contract laboratories maintaining ISO-certified or GMP-compliant quality systems, which can provide a higher level of assurance than some in-house capabilities.
ISO 17025 and Quality Assurance in Disinfectant Testing
A crucial element in the effective validation of disinfectant efficacy is a laboratory’s experience and capability in performing this very involved and meticulous testing. A good indicator that a laboratory can effectively conduct disinfectant efficacy testing (DET) is adherence to international laboratory standards, most notably ISO 17025. This standard specifies the general requirements for the competence, impartiality, and consistent operation of laboratories conducting testing and calibration.
For disinfectant testing, ISO 17025 accreditation ensures that laboratories follow robust quality management systems and use validated methodologies, enabling them to generate scientifically credible and reproducible results. When supplier data is generated according to ISO 17025 standards, organizations may have greater confidence in the integrity and reliability of the findings, increasing regulatory acceptance and support for risk-based validation strategies.
Regulatory Support for a Risk-Based Approach
The FDA’s 2004 guidance on sterile drug products produced by aseptic processing does not specifically permit or prohibit the use of supplier or third-party data. However, this guidance recognizes that facility specific isolates should be assessed within the disinfectant efficacy studies (2). As such, the use of supplier data, if scientifically robust and credible, can be used in support of end-user generated validation data.
The 2022 revision of EU GMP Annex 1 states that: “The disinfection process should be validated. Validation studies should demonstrate the suitability and effectiveness of disinfectants in the specific manner in which they are used and on the type of surface material…” (3).
Supplier registration data that utilizes only suspension testing or limited surface analysis (such as testing efficacy only on stainless steel) is not sufficient for end-user validation. However, an expanded data set on relevant surface materials from the supplier may be utilized providing it adequately reflects and represents the surfaces found within the end users own facility and intended disinfectant use, such as disinfection contact time and application method. This should be accepted based on documented risk analysis which can include the selection of surfaces via a bracketing approach of surface characteristics such as topography and hydrophobicity to determine a worst case and most challenging assessment.
Similarly to EU GMP Annex 1, USP Chapter <1072> on disinfectants and antiseptics (4) acknowledges that disinfectants often come with label claims and efficacy data from the manufacturer (e.g., AOAC or EN standard tests). However, it cautions that the way products are tested for their claims on the label may not always fully reflect real-world usage, especially in the exact way they are used within the cleanroom. For this reason, use of supplier data should be appropriately assessed for its relevance to the use and facility of the end user.
WHO GMP guidance for sterile pharmaceutical products (5) does not directly address the role of supplier-provided efficacy data but rather leaves the method of validation to the discretion of the end user, provided the disinfectants are proven to be effective in maintaining aseptic conditions.
Ecolab Validex™: A Benchmark for Supplier Data Platforms
Ecolab’s Validex™ platform stands out as an example of how supplier data can be both generated and leveraged effectively. Designed specifically for cleanroom environments, Validex™ offers a harmonized and scientifically rigorous approach to disinfectant efficacy validation. It employs modified methodologies closely aligned to standard methods including EN 13697 and ASTM E2197, ensuring consistency and reproducibility. The Validex™ data package was generated by a third-party and independent (of Ecolab) ISO 17025 accredited testing laboratory to ensure an unbiased data set and use towards the end users own validation package.
The data aligns with global regulatory expectations as it includes testing on common cleanroom surfaces and relevant microflora. It also provides complete study reports, incorporating neutralizer assessment, recovery validation and comparative assessment of standard parameters that may differ between regions. Validex™ is globally accessible for Ecolab customers, making it a comprehensive and transparent resource.
Advantages of Embracing Supplier Data
Accepting supplier-generated data can significantly enhance operational efficiency by reducing the time and resources required for validation. Supplier generated data sets often exceed the quality of in-house testing in terms of scientific rigor and reproducibility and often have the added benefit of industry expert scrutinization. Leveraging supplier data is identified as an approach to reduce redundancies in validation and provide a scientifically sound starting point for facility-specific qualification as discussed in the PDA Journal of Pharmaceutical Science and Technology Vol 74(6) .When properly justified and documented, they are also widely accepted by regulatory authorities.
By leveraging supplier data, internal teams can redirect their focus toward high-risk or novel validation criteria (such as hard to clean/disinfect surfaces or difficult to kill organisms), optimizing resource allocation and accelerating project timelines.
Challenges and Mitigation Strategies
Despite its benefits, the use of supplier data is not without challenges. One major concern is the applicability of the data to site-specific conditions. This can be addressed through gap assessments and sites performing supplemental testing where needed to address these data gaps.
Regulatory scrutiny is another consideration. Just like the site performing or commissioning DET validation, regulators want to see clear documentation and justification in protocols and reports regarding the independence and impartiality of any data provided - essential to demonstrate compliance. Data integrity and transparency can also be a concern, particularly when access to raw data is limited. Working with qualified suppliers who provide full data packages can mitigate this risk.
Another challenge that can come under regulatory scrutiny, is the question of repeatability over time. While supplier data may demonstrate suitability at the point of validation, it does not always guarantee that the same performance will be observed consistently in site-specific studies months or years later. Small shifts in manufacturing practices, transport conditions, or even environmental influences can affect outcomes in ways that supplier data may not capture. To mitigate this, sites should establish periodic confirmatory testing and trending to ensure that the supplier’s validation remains representative of actual use conditions.
Other challenges include ensuring that there is suitable supplier qualification (to ensure products selected and validated are being manufactured under controlled and consistent conditions, with end users notified of any changes to formulations, labelling or packaging with adequate notice), harmonizing validation methodology and parameters across global sites, managing change control, and avoiding over-reliance on supplier claims. Each of these can be addressed through structured governance, including supplier/vendor audits, well designed and integrated corporate policies, and internal scientific review processes.
Establishing a Governance Framework
To ensure the effective and compliant use of supplier data, organizations should implement a governance framework that includes: • Supplier Qualification: Verifying the supplier’s quality systems and data integrity.
Data Review and Approval: Engaging cross-functional teams to evaluate data packages. • Risk-Based Applicability Assessment: Ensuring the data is relevant to specific facility conditions. • Documentation and Justification: Clearly articulating the rationale for data acceptance in validation protocols. • Periodic Reassessment: Reviewing data periodically to confirm ongoing relevance and compliance.
Beyond Laboratory Testing: Phase III In Situ Assessment
Phase III in situ disinfectant validation is the final stage of disinfectant qualification in pharmaceutical manufacturing, designed to confirm that the selected disinfectants are effective under actual operational conditions. Unlike earlier validation phases that rely on the laboratory-based surface tests, Phase III focuses on real-world application within the controlled cleanroom environment. Disinfection using the same concentrations and contact times assessed in laboratory testing can now be assessed during routine operations through real-life application methods, cleaning equipment and environmental influences. The Phase III validation should be executed via an environmental monitoring program to establish reduction or elimination of microbial contamination pre and post disinfection.
Both European Norm EN 14885(7) and USP <1072> emphasize the importance of in situ testing The goal is to ensure that disinfectants perform effectively against the actual microbial population present in the cleanroom and on surfaces encountered during production.
Phase III typically includes testing on a range of representative surfaces (e.g., stainless steel, epoxy-coated floors, glass, polymeric materials) and may incorporate worst-case scenarios such as high activity areas or difficult-to-clean locations. This phase also verifies that the disinfectant application method, whether by spray, wipe, or mopping delivers consistent coverage and wet contact time to support the laboratory test data. Many end users will also use Phase III to assess cleaning activities and disinfectant residue management.
By integrating EN 14885 compliance with USP <1072> recommendations, Phase III in situ validation provides robust evidence that disinfectants are not only theoretically effective but also practically reliable in the pharmaceutical environment, supporting regulatory expectations outlined in EU GMP Annex 1 and forming a key component of the facility’s contamination control strategy.
Conclusion: A Strategic Evolution in Validation
The acceptance of supplier-generated disinfectant efficacy data marks a strategic evolution in contamination control. Platforms like Validex™ offer scientifically robust, globally harmonized data that not only meet regulatory expectations but also support operational excellence.
By adopting a structured, risk-based approach to data acceptance and proactively addressing potential challenges, organizations can reduce redundancy, accelerate validation timelines, and uphold the highest standards of compliance and product safety.
